Laurus Labs Limited

LAURUSLABS

INE947Q01028

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:48 2024-04-26 am EDT			5-day change	1st Jan Change
437 ^INR	+2.59%		+2.45%	+1.57%

Apr. 25	Transcript : Laurus Labs Limited, Q4 2024 Earnings Call, Apr 25, 2024
Apr. 25	Laurus Labs' Consolidated Profit Falls in Fiscal Q4	MT

Laurus Labs Limited Reaches to Agreement with Krka to Establish Joint Venture Company in Hyderabad, India Namely Krka Pharma Pvt. Ltd

January 25, 2024 at 06:04 am EST

Laurus Labs Limited announced that it has reached to an agreement with M/s. Krka to establish a joint venture (JV) company in Hyderabad, India (namely Krka Pharma Pvt. Ltd.). In this JV Company, Krka will hold 51% and Laurus 49% shareholding.

The registered capital of the newly founded company shall be up to Indian rupees equivalent to EUR 50 million. The joint venture will enable the production of finished products for the new markets, including the Indian market. It is expected that the necessary procedures and documentation for the registration of the new joint venture company will be finalised by the end of March 2024.

Laurus and KRKA have agreed on a step-by-step development of the joint venture company.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	LAURUS LABS LIMITED	437 INR	+2.59%	+2.45%	2.82B
	KRKA, D. D.	125.5 EUR	+0.40%	-0.40%	4.13B

Latest news about Laurus Labs Limited

Transcript : Laurus Labs Limited, Q4 2024 Earnings Call, Apr 25, 2024	Apr. 25
Laurus Labs' Consolidated Profit Falls in Fiscal Q4	Apr. 25	MT
Laurus Labs Limited Approves Second Interim Dividend for the Financial Year 2023-2024, Payable on or After May 17, 2024	Apr. 25	CI
Laurus Labs Limited Approves Board Changes	Apr. 25	CI
Laurus Labs Limited Reports Earnings Results for the Full Year Ended March 31, 2024	Apr. 25	CI
Laurus Labs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	Apr. 25	CI
Laurus Labs Board to Consider Second Interim Dividend for Fiscal Year 2024	Apr. 18	MT
Laurus Labs Incorporates New JV Company with Slovenia-Based Pharmaceutical Company	Apr. 15	MT
Laurus Labs, Slovenia's Krka to Form JV; Laurus Shares Fall 6%	Jan. 26	MT
Laurus Labs Limited Reaches to Agreement with Krka to Establish Joint Venture Company in Hyderabad, India Namely Krka Pharma Pvt. Ltd	Jan. 25	CI
Jefferies Adjusts Laurus Labs’ Price Target to INR250 From INR290, Keeps at Underperform	Jan. 25	MT
Laurus Labs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 24	CI
Transcript : Laurus Labs Limited, Q3 2024 Earnings Call, Jan 24, 2024	Jan. 24
INDIA STOCKS-IT drives losses in Indian shares ahead of Fed policy outcome	Dec. 12	RE
Indian shares set to open higher; focus turns to Fed policy	Dec. 12	RE
Laurus Labs Completes Acquisition of Additional Stake in Laurus Bio	Nov. 21	MT
Laurus Labs Limited completed the acquisition of additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders.	Nov. 19	CI
Jefferies Adjusts Laurus Labs’ Price Target to INR260 From INR250, Keeps at Underperform	23-10-23	MT
Laurus Labs Limited Announces Resignation of Chandrakanth Chereddi as Non-Executive Director	23-10-20	CI
Transcript : Laurus Labs Limited, Q2 2024 Earnings Call, Oct 20, 2023	23-10-20
Laurus Labs Limited Approves Interim Dividend, Payable on or After November 09, 2023	23-10-20	CI
Laurus Labs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-20	CI
Laurus Labs Limited agreed to acquire an additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders for approximately INR 720 million.	23-09-10	CI
India's Divi's Labs Q1 profit slumps on drug pricing pressures	23-08-14	RE
Laurus Labs' Consolidated Profit Tanks in Fiscal Q1; Shares Climb 4%	23-07-31	MT

Chart Laurus Labs Limited

Duration

Period

More charts

Company Profile

Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. The Company operates through three segments: Laurus Generics, Laurus Synthesis, and Laurus Bio. The Laurus Generics segment comprises API and FDF-Development, manufacture and sale of APIs and advanced intermediates and oral solid formulations/FDF. Laurus Synthesis segment comprises key starting materials (KSM), intermediates and APIs for new chemical entities (NCEs). Laurus Bio segment comprises recombinant products, animal origin free products for safer and viral free bio manufacturing. The Company operates through two geographical segments: Revenue from customers within India-Domestic, and Revenue from customers outside India-Exports. The Company sell its APIs in 56 countries.

Sector

Pharmaceuticals

Calendar

2024-07-11 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Laurus Labs Limited

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

437 INR

Average target price

375.5 INR

Spread / Average Target

-14.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LAURUS LABS LIMITED	+1.57%	2.82B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals